Uniqure (NASDAQ:QURE) had its price objective lifted by SunTrust Banks to $76.00 in a research report report published on Tuesday morning, The Fly reports. SunTrust Banks currently has a buy rating on the biotechnology company’s stock.
Other analysts have also recently issued research reports about the company. BidaskClub cut Uniqure from a hold rating to a sell rating in a research report on Tuesday, April 16th. Robert W. Baird assumed coverage on Uniqure in a research report on Thursday, March 28th. They issued an outperform rating and a $85.00 price objective for the company. Piper Jaffray Companies assumed coverage on Uniqure in a research report on Friday, April 12th. They issued an overweight rating and a $80.00 price objective for the company. HC Wainwright reissued a buy rating on shares of Uniqure in a research report on Tuesday, February 26th. Finally, Zacks Investment Research cut Uniqure from a strong-buy rating to a hold rating in a research report on Wednesday, March 6th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $75.82.
Shares of NASDAQ QURE opened at $61.10 on Tuesday. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -26.11 and a beta of 0.99. Uniqure has a 12-month low of $21.98 and a 12-month high of $69.60.
Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. As a group, equities research analysts expect that Uniqure will post -3.06 EPS for the current year.
In related news, CEO Matthew C. Kapusta sold 67,376 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $63.96, for a total value of $4,309,368.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Alexander Edward Kuta III sold 8,000 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $35.82, for a total value of $286,560.00. The disclosure for this sale can be found here. Insiders sold a total of 82,922 shares of company stock valued at $5,043,369 in the last three months. Insiders own 1.56% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Harvest Group Wealth Management LLC purchased a new position in Uniqure in the 1st quarter worth $26,000. Advisor Group Inc. raised its stake in Uniqure by 5.3% in the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 502 shares during the last quarter. Pearl River Capital LLC purchased a new position in Uniqure in the 1st quarter worth $32,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Uniqure by 14.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,045 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 648 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Uniqure by 264.2% in the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 700 shares during the last quarter. Institutional investors own 60.16% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.